|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-6-10
|
|
pubmed:abstractText |
Urine survivin is a predictive/prognostic molecular marker that detects transitional cell carcinoma (TCC) with high specificity and sensitivity. The presence of urine survivin in patients with TCC who receive intravesical instillation of bacillus Calmette-Guerin or mitomycin C may predict recurrence.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/BCG Vaccine,
http://linkedlifedata.com/resource/pubmed/chemical/BIRC5 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Inhibitor of Apoptosis Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Microtubule-Associated Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Mitomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
170
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
230-4
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12796695-Adjuvants, Immunologic,
pubmed-meshheading:12796695-Administration, Intravesical,
pubmed-meshheading:12796695-Aged,
pubmed-meshheading:12796695-Aged, 80 and over,
pubmed-meshheading:12796695-Antibiotics, Antineoplastic,
pubmed-meshheading:12796695-Antigens, Neoplasm,
pubmed-meshheading:12796695-BCG Vaccine,
pubmed-meshheading:12796695-Carcinoma, Transitional Cell,
pubmed-meshheading:12796695-Female,
pubmed-meshheading:12796695-Humans,
pubmed-meshheading:12796695-Immunoblotting,
pubmed-meshheading:12796695-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:12796695-Male,
pubmed-meshheading:12796695-Microtubule-Associated Proteins,
pubmed-meshheading:12796695-Middle Aged,
pubmed-meshheading:12796695-Mitomycin,
pubmed-meshheading:12796695-Neoplasm Proteins,
pubmed-meshheading:12796695-Neoplasm Recurrence, Local,
pubmed-meshheading:12796695-Predictive Value of Tests,
pubmed-meshheading:12796695-Prognosis,
pubmed-meshheading:12796695-Treatment Outcome,
pubmed-meshheading:12796695-Tumor Markers, Biological,
pubmed-meshheading:12796695-Urinary Bladder Neoplasms
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
|
|
pubmed:affiliation |
Department of Surgery, Section of Urology, Yale University School of Medicine, PO Box 208041 YPB-3, New Haven, CT 06520-8041, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
